JP7439372B2 - ヘテロ二量体タンパク質及びその使用 - Google Patents

ヘテロ二量体タンパク質及びその使用 Download PDF

Info

Publication number
JP7439372B2
JP7439372B2 JP2020571400A JP2020571400A JP7439372B2 JP 7439372 B2 JP7439372 B2 JP 7439372B2 JP 2020571400 A JP2020571400 A JP 2020571400A JP 2020571400 A JP2020571400 A JP 2020571400A JP 7439372 B2 JP7439372 B2 JP 7439372B2
Authority
JP
Japan
Prior art keywords
protein
amino acid
heterodimeric
cells
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020571400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527700A (ja
JP2021527700A5 (cg-RX-API-DMAC7.html
Inventor
シュライバー、テイラー
フロム、ジョージ
シルヴァ、スレシュ ダ
Original Assignee
シャタック ラボ,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャタック ラボ,インコーポレイテッド filed Critical シャタック ラボ,インコーポレイテッド
Publication of JP2021527700A publication Critical patent/JP2021527700A/ja
Publication of JP2021527700A5 publication Critical patent/JP2021527700A5/ja
Priority to JP2023098823A priority Critical patent/JP7452932B2/ja
Application granted granted Critical
Publication of JP7439372B2 publication Critical patent/JP7439372B2/ja
Priority to JP2024032407A priority patent/JP2024057087A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020571400A 2018-06-21 2019-06-21 ヘテロ二量体タンパク質及びその使用 Active JP7439372B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023098823A JP7452932B2 (ja) 2018-06-21 2023-06-15 ヘテロ二量体タンパク質及びその使用
JP2024032407A JP2024057087A (ja) 2018-06-21 2024-03-04 ヘテロ二量体タンパク質及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862688167P 2018-06-21 2018-06-21
US62/688,167 2018-06-21
US201862703248P 2018-07-25 2018-07-25
US62/703,248 2018-07-25
PCT/US2019/038451 WO2019246508A1 (en) 2018-06-21 2019-06-21 Heterodimeric proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023098823A Division JP7452932B2 (ja) 2018-06-21 2023-06-15 ヘテロ二量体タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2021527700A JP2021527700A (ja) 2021-10-14
JP2021527700A5 JP2021527700A5 (cg-RX-API-DMAC7.html) 2022-06-28
JP7439372B2 true JP7439372B2 (ja) 2024-02-28

Family

ID=68983045

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020571400A Active JP7439372B2 (ja) 2018-06-21 2019-06-21 ヘテロ二量体タンパク質及びその使用
JP2023098823A Active JP7452932B2 (ja) 2018-06-21 2023-06-15 ヘテロ二量体タンパク質及びその使用
JP2024032407A Pending JP2024057087A (ja) 2018-06-21 2024-03-04 ヘテロ二量体タンパク質及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023098823A Active JP7452932B2 (ja) 2018-06-21 2023-06-15 ヘテロ二量体タンパク質及びその使用
JP2024032407A Pending JP2024057087A (ja) 2018-06-21 2024-03-04 ヘテロ二量体タンパク質及びその使用

Country Status (10)

Country Link
US (3) US10995127B2 (cg-RX-API-DMAC7.html)
EP (1) EP3810172A4 (cg-RX-API-DMAC7.html)
JP (3) JP7439372B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210025054A (cg-RX-API-DMAC7.html)
CN (1) CN112566650A (cg-RX-API-DMAC7.html)
AU (1) AU2019290192A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020026112A2 (cg-RX-API-DMAC7.html)
CA (1) CA3103975A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020014031A (cg-RX-API-DMAC7.html)
WO (1) WO2019246508A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566650A (zh) * 2018-06-21 2021-03-26 沙塔克实验室有限公司 异二聚体蛋白及其用途
WO2021041958A1 (en) * 2019-08-30 2021-03-04 Shattuck Labs. Inc. Chimeric proteins in autoimmunity
US20230226202A1 (en) * 2020-03-30 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Il-2/il15 compositions and methods of use thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
KR20240007256A (ko) 2021-05-12 2024-01-16 어플라이드 바이오메디컬 사이언스 인스티튜트 이황화 결합된 결합 폴리펩타이드의 스크리닝 및 발현 방법
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
EP4511054A4 (en) * 2022-04-20 2026-07-22 Neptune Biosciences Llc ORTHOGONAL CYTOKINE/IL-21 RECEPTOR SYSTEMS
CN119546322A (zh) 2022-05-16 2025-02-28 恩科弗洛斯生物科学股份有限公司 血脑屏障易位肽和相关分子及其使用方法
WO2024019984A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof
AU2023379740A1 (en) 2022-11-16 2025-05-29 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025133115A1 (en) * 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
CN122555718A (zh) * 2023-12-27 2026-08-11 上海药明生物技术有限公司 重组il-27蛋白及其制备方法
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用
US12698309B2 (en) * 2024-08-01 2026-08-04 Twilight Bioscience, Inc. HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use
WO2026093414A1 (en) * 2024-10-30 2026-05-07 Ose Immunotherapeutics Lipid-based nanoparticles comprising membrane il-35

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505431A (ja) 1999-07-21 2003-02-12 レキシジェン ファーマシューティカルズ コーポレイション タンパク質抗原およびペプチド抗原の免疫原性を増強するためのfc融合タンパク質
JP2003507012A (ja) 1999-08-09 2003-02-25 レキシジェン ファーマシューティカルズ コーポレイション 複合サイトカイン−抗体複合体
JP2008019258A (ja) 1996-02-20 2008-01-31 Applied Res Syst Ars Holding Nv ヘテロ二量体を形成するハイブリッドタンパク質
JP2015180226A (ja) 2009-12-29 2015-10-15 エマージェント プロダクト デベロップメント シアトル, エルエルシー ヘテロダイマー結合タンパク質およびその使用
WO2017059168A1 (en) 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
JP2017529345A (ja) 2014-09-17 2017-10-05 ジェネンテック, インコーポレイテッド 抗her2抗体を含む免疫複合体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031480A1 (en) * 1994-05-18 1995-11-23 S.P.I. Synthetic Peptides Incorporated Heterodimer polypeptide immunogen carrier composition and method
IT1274350B (it) * 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
ES2221717T3 (es) * 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
AU2001290524A1 (en) * 2000-08-08 2002-02-18 Zymogenetics Inc. Soluble zcytor 11 cytokine receptors
EP1781708B1 (en) * 2004-07-09 2011-02-16 Variety Children's Hospital d/b/a/ Miami Children's Hospital Materials and methods for immune system stimulation
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
CN102712696A (zh) * 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
SG11201707182WA (en) * 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
MX2018001208A (es) * 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
US12447213B2 (en) * 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
IL268198B2 (en) * 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
CN112566650A (zh) * 2018-06-21 2021-03-26 沙塔克实验室有限公司 异二聚体蛋白及其用途
BR112021013193A2 (pt) * 2019-01-07 2021-09-28 Shattuck Labs, Inc. Proteínas heterodiméricas para modulação de células t gama delta
WO2021041958A1 (en) * 2019-08-30 2021-03-04 Shattuck Labs. Inc. Chimeric proteins in autoimmunity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008019258A (ja) 1996-02-20 2008-01-31 Applied Res Syst Ars Holding Nv ヘテロ二量体を形成するハイブリッドタンパク質
JP2003505431A (ja) 1999-07-21 2003-02-12 レキシジェン ファーマシューティカルズ コーポレイション タンパク質抗原およびペプチド抗原の免疫原性を増強するためのfc融合タンパク質
JP2003507012A (ja) 1999-08-09 2003-02-25 レキシジェン ファーマシューティカルズ コーポレイション 複合サイトカイン−抗体複合体
JP2015180226A (ja) 2009-12-29 2015-10-15 エマージェント プロダクト デベロップメント シアトル, エルエルシー ヘテロダイマー結合タンパク質およびその使用
JP2017529345A (ja) 2014-09-17 2017-10-05 ジェネンテック, インコーポレイテッド 抗her2抗体を含む免疫複合体
WO2017059168A1 (en) 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAO, Peng et al.,"Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent",Mediators of Inflammation,2017年,Vol. 2017,p.1-8,DOI: 10.1155/2017/5931865
HA, Ji-Hee et al.,"Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins",Frontiers in Immunology,2016年10月06日,Vol. 7,DOI: 10.3389/fimmu.2016.00394
HOSHINO, Hitomi et al.,"An Integrin α4β7・IgG Heterodimeric Chimera Binds to MAdCAM-1 on High Endothelial Venules in Gut-Associated Lymphoid Tissue",Journal of Histochemistry & Cytochemistry,2011年03月23日,Vol. 59, No. 6,p.572-583,DOI: 10.1369/0022155411404416
RYU, Jun-Geol et al.,"Treatment of IL-21R-Fc control autoimmune arthritis via suppression of STAT3 signal pathway mediated regulation of the Th17/Treg balance and plasma B cells",Immunology Letters,2015年02月,Vol. 163, No. 2,p.143-150,DOI: 10.1016/j.imlet.2014.09.007

Also Published As

Publication number Publication date
JP2024057087A (ja) 2024-04-23
US11780897B2 (en) 2023-10-10
KR20210025054A (ko) 2021-03-08
JP2021527700A (ja) 2021-10-14
US20200079831A1 (en) 2020-03-12
EP3810172A1 (en) 2021-04-28
AU2019290192A1 (en) 2021-01-07
MX2020014031A (es) 2021-05-12
BR112020026112A2 (pt) 2021-04-06
JP2023116718A (ja) 2023-08-22
US20210214409A1 (en) 2021-07-15
CA3103975A1 (en) 2019-12-26
CN112566650A (zh) 2021-03-26
EP3810172A4 (en) 2022-04-20
JP7452932B2 (ja) 2024-03-19
US20230220030A1 (en) 2023-07-13
WO2019246508A1 (en) 2019-12-26
US10995127B2 (en) 2021-05-04

Similar Documents

Publication Publication Date Title
JP7452932B2 (ja) ヘテロ二量体タンパク質及びその使用
JP7620045B2 (ja) Tigit及びlightベースのキメラタンパク質
JP7303254B2 (ja) I型及びii型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
CA3149583A1 (en) Chimeric proteins in autoimmunity
RU2775490C2 (ru) Химерные белки на основе tigit и light
HK40091905A (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
HK40092182A (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240126

R150 Certificate of patent or registration of utility model

Ref document number: 7439372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150